New TGCT Educational Program Explores Emerging Systemic Treatment Options October 14, 2026 PeerView Institute for Medical Education and SARC have launched an educational activity exploring emerging clinical evidence and systemic treatment options for patients with tenosynovial giant cell tumor (TGCT) whose disease is not amenable to surgery or is recurrent or progressive. Featuring expert perspectives and a patient advocate, the program highlights evolving treatment strategies and patient-centered care. Healthcare professionals can gain practical insights into identifying patients who may benefit from colony-stimulating factor 1 receptor (CSF1R) inhibitors and incorporating these therapies into treatment decisions. Click here to watch the program Categories: Education, Sarcoma News